MindMed Provides Status Update on IND for Phase 2b Trial of LSD for the Treatment of Generalized Anxiety Disorder

NEW YORK, Dec. 21, 2021. Mind Medicine (MindMed) Inc. (the " Company " ), a leading biotech company developing psychedelic-inspired therapies, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its IND...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials